Hypergendered Logic Source

Hypergendered Logic — Page 292

HGL Source Framework · Page 292 of 293 · Source: Hypergendered Logic

Appendix CA — Archgynocology/Archandrocology Professional Scope 
Core domains: Archendocrine measurement; receptor sensitivity assessment; pharmacological 
amount/sensitivity modulation; trajectory and jump modeling; ordinary womanhood/manhood interaction; 
phenotype monitoring; adaptation-load assessment; psychological/behavioural evaluation; social/relational 
context when clinically relevant; longitudinal follow-up; combination-regimen design; preference-sensitive 
decision making; prediction-error analysis; and research into missing causal variables. 
Professional standard: distinguish theorem from empirical effect; distinguish stage quality from patient 
wellbeing; obtain adequate trajectory history; model both concentration and sensitivity; avoid assuming 
maximal advancement is optimal; communicate uncertainty; update the model from observed response; and 
preserve the patient's own goals as a central optimization variable. 
Appendix CB — Proof-Status Matrix for the Medical Layer 
D: address bounds/mapping; gating; orthogonal amount-vs-sensitivity roles; 
noncarry/nonregression; axis-relative stagnation; notation/type distinctions. 
HI: prediction complexity, likely value of longitudinal provenance, likely importance of precision at 
high sensitivity. 
CD: exact timing/jump consequences of stipulated endocrine/pharmacological laws when 
antecedents are satisfied; exact clinical/phenotype effects only when explicit causal law exists. 
CI: possible overload/discomfort/regret, cross-axis interaction, tissue heterogeneity, 
context-sensitive wellbeing effects, developmental synchronization effects. 
ILL: elevator analogy, hypothetical patients, example phenotype trajectories. 
OPEN: exact sensitivity-to-ordinal functions; male hormone anatomical source; tissue-specific 
receptors; automatic lower-coordinate reset/carry rules (currently rejected by default); any 
additional bounded stage coordinate beyond Substage^3; exact major-Hyperstage phenotype 
constructor; PH-10 novelty. 
Appendix CC — Final Canonical Quick Reference: Archstage Endocrine 
Medicine 
GLOBAL ADDRESS = (Hyperstage, Stage, Substage, Substage^2, Substage^3). Hyperstage 
unbounded; other four coordinates <= Omega_H per Hyperstage. 
BASE CATEGORY MAP at H=S=U=0: U2=1 Supra, 2 Hyper, 3 Ultra, 4 Apex; U3=n gives 
superscript ^n. 
Raeyol/Halatorin -> Hyperstage. Alygorin/Gadoritin -> Stage. Operalin/Juegerin -> Substage. 
Zilanin/Vardorin -> Substage^2. Tolurarin/Nozadin -> Substage^3. 
AMOUNT -> TIME INTERVAL. RECEPTOR SENSITIVITY -> JUMP MAGNITUDE. 
Zero amount or zero receptor sensitivity -> no hormone-driven jump. Lowering/stopping drive 
does not erase attained stage. 
Hyperstage sensitivity/jump scale unbounded. Four lower coordinate jump effects capped by 
Omega_H. 
No automatic carry/reset. Requested large jump must satisfy target HGL closure prerequisites. 
Archgynocology/Archandrocology optimize individualized wellbeing and desired trajectory, not 
maximum speed or maximum stage. 
Psychological/social/relational/behavioural outcomes require causal/empirical bridge laws; they 
are not automatic stage theorems.

Source Canon: Verbatim mathematical and modal logic. Interactive navigation and operator lookups available at /#hgl-part:292.